Page last updated: 2024-12-07
4,4'-azobis(phenol)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4'-azobis(phenol): isolated from fungus Agaricus xanthodermus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 101245 |
| CHEMBL ID | 116175 |
| SCHEMBL ID | 901189 |
| MeSH ID | M0131146 |
Synonyms (48)
| Synonym |
|---|
| 4,4-dihydroxyazobenzene |
| nsc-402595 |
| 2050-16-0 |
| nsc402595 |
| CHEMBL116175 |
| AKOS003619052 |
| 4-[(4-hydroxyphenyl)hydrazinylidene]cyclohexa-2,5-dien-1-one |
| 4,4'-azobis(phenol) |
| nsc 402595 |
| phenol, 4,4'-azobis- |
| ai3-08894 |
| 4,4'-dihydroxyazobenzene |
| 4-[(4-hydroxyphenyl)diazenyl]phenol |
| phenol,4,4'-(1,2-diazenediyl)bis- |
| 4-(4-hydroxyphenylazo)phenol |
| trans-4,4'-azodiphenol |
| unii-f4ylc7i7dn |
| phenol, 4,4'-(1,2-diazenediyl)bis- |
| p-azophenol |
| phenol, 4,4'-azodi |
| 4,4'-azodiphenol |
| 51437-66-2 |
| phenol, 4,4'-(1e)-1,2-diazenediylbis- |
| f4ylc7i7dn , |
| p,p'-dihydroxyazobenzene |
| SCHEMBL901189 |
| WKODVHZBYIBMOC-UHFFFAOYSA-N |
| WKODVHZBYIBMOC-BUHFOSPRSA-N |
| di-(4-hydroxy-phenyl)-diazene |
| D3431 |
| AKOS028112956 |
| mfcd00045778 |
| SY056471 |
| 4,4 inverted exclamation mark -dihydroxyazobenzene |
| (e)-4,4-(diazene-1,2-diyl)diphenol pound ws201781 pound(c) |
| E72619 |
| AS-18987 |
| 10.14272/WKODVHZBYIBMOC-BUHFOSPRSA-N |
| doi:10.14272/wkodvhzbyibmoc-buhfosprsa-n.1 |
| (e)-4,4'-(diazene-1,2-diyl)diphenol |
| N10032 |
| Q27277636 |
| A910719 |
| YSWG059 |
| 4,4-(diazene-1,2-diyl)diphenol |
| CAA05016 |
| 4,4'-(e)-diazene-1,2-diyldiphenol |
| CS-W018449 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1127148 | Binding affinity to ERalpha (unknown origin) relative to estradiol | 2014 | Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8 | Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor. |
| AID481675 | Induction of human ApoA-1 gene expression in human Caco-2 cells co-transfected with luc-beta-galactosidase after 48 hrs assessed as luciferase activity by luminometer relative to resveratrol | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Stilbene analogs as inducers of apolipoprotein-I transcription. |
| AID481674 | Induction of human ApoA-1 gene expression in human Caco-2 cells co-transfected with luc-beta-galactosidase after 48 hrs assessed as luciferase activity by luminometer relative to control | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Stilbene analogs as inducers of apolipoprotein-I transcription. |
| AID216186 | The compound was tested for antiviral activity against Herpes simplex virus type-1 in the vero cells using plaque inhibition assay; no IC50 reached without damage to the cell monolayer. | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17 | Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||